


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name	Steven F. Goldstein		
Signature		Date	April 24, 2003

<p style="text-align: center;">PETITION FROM REQUIREMENT FOR RESTRICTION PURSUANT TO 37 CFR §1.144</p> <p>Address to: Assistant Commissioner for Patents Washington, D.C. 20231</p>	Attorney Docket	IRVN-007CON
	First Named Inventor	Gale A. Granger
	Application Number	09/712,813
	Filing Date	November 13, 2000
	Group Art Unit	1646
	Confirmation Number	4642
	Examiner Name	Joseph F. Murphy
	Title	"Treating Arthritis with TNF Receptor Releasing Enzyme"

Dear Sir:

Applicants hereby petition the Commissioner to review the Restriction Requirement issued in this application, dated March 15, 2002 (Paper No. 10), and made final on August 13, 2002 (Paper No. 13). The Restriction Requirement was properly traversed in applicants' response filed on June 17, 2002 (Paper No. 12).

Specifically, applicants petition against the division between SEQ. ID NOs:1-10 and 147-154 throughout the restriction. Applicants request the following remedy:

- Rejoinder of Groups I-XVI into one group
- Rejoinder of Groups XVII-XXIII into one group
- Rejoinder of Groups XXIV-XXXII into one group
- Rejoinder of Groups XXXIII-XL into one group
- Rejoinder of Groups XLI-LI into one group
- Rejoinder of Groups LII-LIX into one group
- Rejoinder of Groups LX-LXX into one group.

Applicants do not traverse restriction between the categories of polynucleotides, polypeptides, methods of producing polypeptides, antibody, methods of producing antibody, methods for determining altered TRRE activity, methods for screening TRRE modulators, methods for decreasing signal transduction, or methods for screening polynucleotides for TRRE activity.

04/30/2003 CNGUYEN 00000144 500815 09712813

01 FC:1460

130.00 CH

1

RECEIVED

JUL 14 2003

TECH CENTER 1600/2900

The restriction between the SEQ. ID NOs is improper because SEQ. ID NOs:1-10 and 147-154 were all searched fully in priority application 09/081,385. MPEP § 803 states that no restriction is permitted if it would not be a burden on the Examiner to consider the claimed subject matter together, even where it encompasses more than one independent or distinct inventions. Since the sequences have all been previously searched, there is no burden on the Examiner to consider the sequences together within any one of the categories of products or methods.

Since the Restriction between the sequences should not have been made, this Petition has been necessitated by an error of the Office. Accordingly, applicants request that the fee paid for consideration of this Petition be refunded to the Deposit Account.


The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 Order No. IRVN-007CON.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

April 24, 2003

By:


Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\IRVN (UC Irvine)\007con\Petition to Review Rest Req.doc